vs

Side-by-side financial comparison of Apyx Medical Corp (APYX) and Sunlands Technology Group (STG). Click either name above to swap in a different company.

Apyx Medical Corp is the larger business by last-quarter revenue ($19.2M vs $10.1M, roughly 1.9× Sunlands Technology Group). Sunlands Technology Group runs the higher net margin — 24.0% vs -6.8%, a 30.8% gap on every dollar of revenue. Over the past eight quarters, Apyx Medical Corp's revenue compounded faster (36.8% CAGR vs 0.6%).

Bovie Medical Corporation was an American medical device manufacturer of medical devices, electrosurgical products and energy technologies. It was based in Clearwater, Florida with a manufacturing facility in Bulgaria.

STG Partners, LLC (STG) is an American private equity firm and based in Menlo Park, California. Its predecessor, Symphony Technology Group ("Symphony") was founded in 2002 by Romesh Wadhwani, William Chisholm, and Bryan Taylor. In 2017, Symphony was reorganized as STG Partners. As of March 2025, STG Partners managed approximately $12 billion in 19 pooled investment vehicle for its clients. The firm itself has less than one billion dollars in assets.

APYX vs STG — Head-to-Head

Bigger by revenue
APYX
APYX
1.9× larger
APYX
$19.2M
$10.1M
STG
Higher net margin
STG
STG
30.8% more per $
STG
24.0%
-6.8%
APYX
Faster 2-yr revenue CAGR
APYX
APYX
Annualised
APYX
36.8%
0.6%
STG

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
APYX
APYX
STG
STG
Revenue
$19.2M
$10.1M
Net Profit
$-1.3M
$2.4M
Gross Margin
62.6%
88.5%
Operating Margin
0.1%
26.5%
Net Margin
-6.8%
24.0%
Revenue YoY
34.7%
Net Profit YoY
71.9%
EPS (diluted)

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
APYX
APYX
STG
STG
Q4 25
$19.2M
Q3 25
$12.9M
$10.1M
Q2 25
$11.4M
$9.3M
Q1 25
$9.4M
Q4 24
$14.2M
$9.7M
Q3 24
$11.5M
Q2 24
$12.1M
$10.0M
Q1 24
$10.2M
Net Profit
APYX
APYX
STG
STG
Q4 25
$-1.3M
Q3 25
$-2.0M
$2.4M
Q2 25
$-3.8M
$1.4M
Q1 25
$-4.2M
Q4 24
$-4.6M
$1.8M
Q3 24
$-4.7M
Q2 24
$-6.6M
$2.2M
Q1 24
$-7.6M
Gross Margin
APYX
APYX
STG
STG
Q4 25
62.6%
Q3 25
64.4%
88.5%
Q2 25
62.3%
85.2%
Q1 25
60.1%
Q4 24
63.0%
83.3%
Q3 24
60.5%
Q2 24
61.7%
85.2%
Q1 24
58.1%
Operating Margin
APYX
APYX
STG
STG
Q4 25
0.1%
Q3 25
-6.5%
26.5%
Q2 25
-22.6%
15.2%
Q1 25
-32.4%
Q4 24
-21.4%
13.4%
Q3 24
-31.6%
Q2 24
-45.7%
Q1 24
-64.6%
Net Margin
APYX
APYX
STG
STG
Q4 25
-6.8%
Q3 25
-15.4%
24.0%
Q2 25
-33.2%
15.4%
Q1 25
-44.0%
Q4 24
-32.5%
18.2%
Q3 24
-40.9%
Q2 24
-54.0%
21.5%
Q1 24
-74.0%
EPS (diluted)
APYX
APYX
STG
STG
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
$-0.19
$0.31
Q1 24
$-0.22

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
APYX
APYX
STG
STG
Cash + ST InvestmentsLiquidity on hand
$31.7M
$15.1M
Total DebtLower is stronger
$37.5M
Stockholders' EquityBook value
$14.5M
$17.7M
Total Assets
$66.8M
$41.2M
Debt / EquityLower = less leverage
2.58×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
APYX
APYX
STG
STG
Q4 25
$31.7M
Q3 25
$25.1M
$15.1M
Q2 25
$29.3M
Q1 25
$31.0M
Q4 24
$31.7M
$15.6M
Q3 24
$28.0M
Q2 24
$32.7M
$18.7M
Q1 24
$37.3M
Total Debt
APYX
APYX
STG
STG
Q4 25
$37.5M
Q3 25
$37.5M
Q2 25
$37.5M
Q1 25
$37.5M
Q4 24
$37.5M
$1.5M
Q3 24
$37.5M
Q2 24
$1.8M
Q1 24
Stockholders' Equity
APYX
APYX
STG
STG
Q4 25
$14.5M
Q3 25
$5.8M
$17.7M
Q2 25
$7.3M
$12.6M
Q1 25
$10.5M
Q4 24
$14.2M
$10.7M
Q3 24
$11.0M
Q2 24
$14.7M
$7.6M
Q1 24
$20.3M
Total Assets
APYX
APYX
STG
STG
Q4 25
$66.8M
Q3 25
$57.4M
$41.2M
Q2 25
$58.2M
$40.3M
Q1 25
$60.2M
Q4 24
$64.8M
$42.4M
Q3 24
$60.7M
Q2 24
$65.4M
$41.3M
Q1 24
$70.7M
Debt / Equity
APYX
APYX
STG
STG
Q4 25
2.58×
Q3 25
6.41×
Q2 25
5.17×
Q1 25
3.57×
Q4 24
2.64×
0.14×
Q3 24
3.40×
Q2 24
0.24×
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
APYX
APYX
STG
STG
Operating Cash FlowLast quarter
$-2.5M
Free Cash FlowOCF − Capex
$-2.8M
FCF MarginFCF / Revenue
-14.6%
Capex IntensityCapex / Revenue
1.4%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-9.1M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
APYX
APYX
STG
STG
Q4 25
$-2.5M
Q3 25
$-3.5M
Q2 25
$-1.2M
Q1 25
$-702.0K
Q4 24
$-2.9M
Q3 24
$-4.4M
Q2 24
$-4.3M
Q1 24
$-6.3M
Free Cash Flow
APYX
APYX
STG
STG
Q4 25
$-2.8M
Q3 25
$-4.1M
Q2 25
$-1.5M
Q1 25
$-757.0K
Q4 24
$-3.2M
Q3 24
$-4.6M
Q2 24
$-4.6M
Q1 24
$-6.4M
FCF Margin
APYX
APYX
STG
STG
Q4 25
-14.6%
Q3 25
-31.5%
Q2 25
-13.2%
Q1 25
-8.0%
Q4 24
-22.4%
Q3 24
-40.0%
Q2 24
-38.0%
Q1 24
-62.2%
Capex Intensity
APYX
APYX
STG
STG
Q4 25
1.4%
Q3 25
4.0%
Q2 25
2.3%
Q1 25
0.6%
Q4 24
1.7%
Q3 24
1.3%
Q2 24
2.4%
Q1 24
0.3%

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons